Halozyme Therapeutics (HALO) Tops Q2 EPS by 15c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $124.83 --0%
Revenue Growth %: +37.6%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: +37.6%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.91, $0.15 better than the analyst estimate of $0.76. Revenue for the quarter came in at $231 million versus the consensus estimate of $208.94 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.65-$4.05, versus the consensus of $4.72. Halozyme Therapeutics sees FY2024 revenue of $0.93-1.01 billion, versus the consensus of $0.98 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spotify (SPOT) Misses Q3 EPS by 36c; misses on guidance
- Honeywell (HON) Tops Q3 EPS by 11c; raises guidance
- Allegion plc (ALLE) Tops Q3 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
